Proactive Investors - Run By Investors For Investors

Clinigen an ‘undervalued opportunity’ – broker

N+1 Singer, which starts covering the stock with a ‘buy’ rating, points out that the drug development group’s services revenues are lumpy, which appears to have put investors off buying the shares this year.

Shares in Clinigen (LON:CLIN) are trading too low, according to broker N+1 Singer.

Analyst Elizabeth Klein, who starts covering the stock with a ‘buy’ rating, points out that the drug development group’s services revenues are lumpy, which appears to have put investors off buying the shares this year.

However, she thinks the improving margins should start tempting investors back to the company, which is still worth more than £300mln after 2013’s strong share price run.

Klein says that with gross margins of 70-80%, the specialty pharma division “should help to grow Clinigen’s profits faster than revenues”.

She notes that this part of the business is still early in the growth phase, with four drugs and with plans to acquire around six more over the next three-five years.

Her target price for the stock is 439p, which is some 70p higher than the current price of 374p.

“The model is still evolving for Clinigen but we expect the highly experienced management team to manage the uneven Services revenue streams over the next few years, and at the same time to acquire new drugs for its rapidly growing Specialty Pharmaceuticals division,” says Klein.

She adds: “We believe the 3m underperformance of the shares may have been due to the expected risk associated with the lumpy Services divisions and the founder’s overhang: 6.4% of the c31% stake was recently sold and performance subsequently improved. 

“Even though there remains significant risk with the timing of Services revenues, the improving margins and the upside to the valuation moderates this.”

 

View full CLIN profile View Profile

Clinigen Group PLC Timeline

Related Articles

scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use